Iovance Biotherapeutics, Inc. filed a Current Report on Form 8-K on October 5, 2026, to update its corporate presentation. The filing states that the company intends to use this updated presentation for healthcare conferences and to communicate with analysts, stockholders, and other interested parties. The presentation, attached as Exhibit 99.1, is incorporated by reference into the filing.
The presentation outlines the company's status as a developer of Tumor-Infiltrating Lymphocyte (TIL) therapy for cancer patients. It highlights that Iovance has two approved products and is focused on commercial launch and financial performance. As of October 5, 2026, the company reports having approximately 100 treatment centers.
Financially, the company provided updated guidance for the full year 2026. The guidance range is set between $410 million and $420 million in revenue, representing an increase of approximately $55 million, or about 15%, over the previous range. The company reported $304 million in cash, cash equivalents, short-term investments, and restricted cash as of June 30, 2026, projecting this cash runway to extend into the second half of 2028.
The filing also details the company's commercial and clinical progress. Iovance reports that approximately 2,000 patients have been treated with its TIL products. The company notes that in the second quarter of 2026, revenue exceeded guidance by more than 10%.
Regarding its pipeline, the presentation outlines a robust development plan for solid tumors. The company is pursuing a Phase 3 confirmatory trial for Lifileucel in frontline advanced melanoma. Additionally, the company has received Fast Track Designation from the U.S. FDA for Lifileucel in metastatic non-small cell lung cancer (mNSCLC), with a potential launch anticipated in the second half of 2027.
